Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.31), Briefing.com reports. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The company had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. During the same period last year, the company posted ($2.33) EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis.

Ultragenyx Pharmaceutical Price Performance

RARE traded down $0.45 during trading hours on Friday, reaching $42.75. 1,143,007 shares of the stock traded hands, compared to its average volume of 767,975. The firm’s fifty day simple moving average is $47.38 and its two-hundred day simple moving average is $44.04. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -5.34 and a beta of 0.68. Ultragenyx Pharmaceutical has a fifty-two week low of $31.52 and a fifty-two week high of $54.98.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the transaction, the executive vice president now directly owns 252,823 shares in the company, valued at approximately $12,623,452.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now directly owns 89,268 shares in the company, valued at approximately $4,799,047.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the transaction, the executive vice president now owns 252,823 shares in the company, valued at $12,623,452.39. The disclosure for this sale can be found here. In the last three months, insiders sold 32,116 shares of company stock valued at $1,645,983. Corporate insiders own 6.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on RARE shares. JPMorgan Chase & Co. upped their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Robert W. Baird increased their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday. Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $88.00.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.